Roche Aktie [WKN: 855167 / ISIN: CH0012032048]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen
Ausblick

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen
Ausblick

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche AG (Genussschein)

05:00		Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer (Roche Holding AG)
06.05.25		Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity (Roche Holding AG)
30.04.25		CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings (Roche Holding AG)
29.04.25		Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer (Roche Holding AG)
25.04.25		New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission (Roche Holding AG)
24.04.25		[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter (Roche Holding AG)
23.04.25		Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) (Roche Holding AG)
22.04.25		Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years (Roche Holding AG)
14.04.25		European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy (Roche Holding AG)
03.04.25		Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025 (Roche Holding AG)
02.04.25		Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis (Roche Holding AG)
25.03.25		Roche Annual General Meeting 2025 (Roche Holding AG)
17.03.25		Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference (Roche Holding AG)
07.03.25		Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston (Roche Holding AG)
05.03.25		FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis (Roche Holding AG)
02.03.25		Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies (Roche Holding AG)
28.02.25		CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
20.02.25		Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology (Roche Holding AG)
12.02.25		FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) (Roche Holding AG)
07.02.25		New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis (Roche Holding AG)
04.02.25		FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness (Roche Holding AG)
31.01.25		Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU (Roche Holding AG)
30.01.25		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth (Roche Holding AG)
29.01.25		Change to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
28.01.25		Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer (Roche Holding AG)
27.01.25		Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) (Roche Holding AG)
22.01.25		Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care (Roche Holding AG)
08.01.25		Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (Roche Holding AG)
19.12.24		Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (Roche Holding AG)
18.12.24		Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (Roche Holding AG)
13.12.24		Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (Roche Holding AG)
10.12.24		New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (Roche Holding AG)
09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (Roche Holding AG)
26.11.24		Roche reports update on Phase III SKYSCRAPER-01 study results (Roche Holding AG)
05.11.24		Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
31.10.24		Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24		New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
23.10.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
18.10.24		Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
14.10.24		Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)

1 | Weiter

Newssuche

Roche Peer Group Nachrichten

12.05.25		Roche-Aktie fester: Roche-Tochter Genentech errichtet Medikamentenproduktion in den USA
12.05.25		Merck-Aktie: Jüngste Einstufung durch Barclays Capital
12.05.25		SMI-Wert Novartis-Aktie: So viel Verlust wäre bei einem Investment in Novartis von vor einem Jahr angefallen
12.05.25		DAX 40-Papier Merck-Aktie: So viel Verlust wäre bei einem Investment in Merck von vor 3 Jahren angefallen
09.05.25		SMI-Titel Roche-Aktie: So viel hätte eine Investition in Roche von vor 10 Jahren gekostet
08.05.25		NASDAQ Composite Index-Titel Gilead Sciences-Aktie: Mit dieser Dividende bereitet Gilead Sciences Anlegern eine Freude
07.05.25		JP Morgan Chase & Co. gibt Merck-Aktie Overweight
06.05.25		S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte eine Pfizer-Investition von vor 10 Jahren eingebracht

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.05.2025 13:52
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie [WKN: 855167 / ISIN: CH0012032048]

Nachrichten zu Roche AG (Genussschein)

Eintrag hinzufügen Eintrag bearbeiten

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten